MannKind Corporation to Present at Investor Conferences in New York

MannKind Corporation, a biopharmaceutical company, will present at two upcoming investor conferences, providing insight into its strategies and progress in developing innovative treatments for chronic diseases.

The company's management team will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, scheduled for Thursday, September 10, 2026, at 11:30 a.m. Eastern Time. Additionally, MannKind will present at the H.C. Wainwright 28th Annual Global Investment Conference, also in New York, on Tuesday, September 15, 2026, at 9:30 a.m. Eastern Time.

Attendees of these conferences will have the opportunity to hear directly from MannKind’s executives about the company’s ongoing research and development efforts, as well as its plans for the future. Live audio webcasts of the presentations will be available on MannKind’s website, and a recorded version will remain accessible for approximately 90 days after the conferences.

MannKind Corporation, based in Danbury, Connecticut, and Westlake Village, California, focuses on transforming chronic disease care through patient-centric solutions. The company’s research and development are centered on cardiometabolic and orphan lung diseases, aiming to develop treatments for serious unmet medical needs, such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Links to the live audio webcasts and recorded versions will be available on the company’s website at [https://investors.mannkindcorp.com/events-and-presentations].